Gilead begins testing inhalable form of remdesivir for coronavirus


Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.

The company said the trial, which will enroll about 60 healthy Americans aged between 18 and 45, will test the drug particularly in those cases where the disease has not progressed to require hospitalisation.  The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration.....

This article is no longer available in our repository.

There could be multiple reasons for this.